Literature DB >> 28795399

New Pharmacogenomics Research Network: An Open Community Catalyzing Research and Translation in Precision Medicine.

M V Relling1, R M Krauss2, D M Roden3, T E Klein4, D M Fowler5,6, N Terada7, L Lin8, M Riel-Mehan9, T P Do9, M Kubo10, S W Yee8, G T Johnson8,9, K M Giacomini8,11.   

Abstract

The goal of pharmacogenomics research is to discover genetic polymorphisms that underlie variation in drug response. Increasingly, pharmacogenomics research involves large numbers of patients and the application of new technologies and methodologies to enable discovery. The Pharmacogenomics Research Network (PGRN) has become a community-driven network of investigators spanning scientific and clinical disciplines. Here, we highlight the activities and types of resources that enable PGRN members to enhance and drive basic and translational research in pharmacogenomics.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Year:  2017        PMID： 28795399      PMCID： PMC5706548          DOI： 10.1002/cpt.755

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  6 in total

1.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

Authors:  Ching-Hon Pui; Charles G Mullighan; William E Evans; Mary V Relling
Journal:  Blood       Date:  2012-06-22       Impact factor: 22.113

Review 3.  Pharmacogenomics knowledge for personalized medicine.

Authors:  M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2012-10       Impact factor: 6.875

4.  Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.

Authors:  S W Yee; Y Momozawa; Y Kamatani; R F Tyndale; R M Weinshilboum; M J Ratain; K M Giacomini; M Kubo
Journal:  Clin Pharmacol Ther       Date:  2016-07-21       Impact factor: 6.875

Review 5.  Overview of the BioBank Japan Project: Study design and profile.

Authors:  Akiko Nagai; Makoto Hirata; Yoichiro Kamatani; Kaori Muto; Koichi Matsuda; Yutaka Kiyohara; Toshiharu Ninomiya; Akiko Tamakoshi; Zentaro Yamagata; Taisei Mushiroda; Yoshinori Murakami; Koichiro Yuji; Yoichi Furukawa; Hitoshi Zembutsu; Toshihiro Tanaka; Yozo Ohnishi; Yusuke Nakamura; Michiaki Kubo
Journal:  J Epidemiol       Date:  2017-02-08       Impact factor: 3.211

6.  Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).

Authors:  Kelly E Caudle; Henry M Dunnenberger; Robert R Freimuth; Josh F Peterson; Jonathan D Burlison; Michelle Whirl-Carrillo; Stuart A Scott; Heidi L Rehm; Marc S Williams; Teri E Klein; Mary V Relling; James M Hoffman
Journal:  Genet Med       Date:  2016-07-21       Impact factor: 8.822
  6 in total
  12 in total

1.  Using Electronic Health Records To Generate Phenotypes For Research.

Authors:  Sarah A Pendergrass; Dana C Crawford
Journal:  Curr Protoc Hum Genet       Date:  2018-12-05

Review 2.  Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.

Authors:  Ricardo Stein; Filipe Ferrari; Fernando Scolari
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

Review 3.  Applying genomics in heart transplantation.

Authors:  Brendan J Keating; Alexandre C Pereira; Michael Snyder; Brian D Piening
Journal:  Transpl Int       Date:  2018-02-12       Impact factor: 3.782

Review 4.  Mind the gap: resources required to receive, process and interpret research-returned whole genome data.

Authors:  Dana C Crawford; Jessica N Cooke Bailey; Farren B S Briggs
Journal:  Hum Genet       Date:  2019-06-03       Impact factor: 4.132

Review 5.  Bridging the Gaps in Personalized Medicine Value Assessment: A Review of the Need for Outcome Metrics across Stakeholders and Scientific Disciplines.

Authors:  William S Bush; Jessica N Cooke Bailey; Mark F Beno; Dana C Crawford
Journal:  Public Health Genomics       Date:  2019-08-27       Impact factor: 2.000

Review 6.  The genomic landscape of pediatric cancers: Implications for diagnosis and treatment.

Authors:  E Alejandro Sweet-Cordero; Jaclyn A Biegel
Journal:  Science       Date:  2019-03-15       Impact factor: 47.728

Review 7.  Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine.

Authors:  Brittney H Davis; Nita A Limdi
Journal:  Clin Pharmacol Ther       Date:  2021-07-29       Impact factor: 6.903

Review 8.  Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Authors:  Ann K Daly; Allan E Rettie; Douglas M Fowler; John O Miners
Journal:  J Pers Med       Date:  2017-12-28

9.  Multiplex assessment of protein variant abundance by massively parallel sequencing.

Authors:  Kenneth A Matreyek; Lea M Starita; Jason J Stephany; Beth Martin; Melissa A Chiasson; Vanessa E Gray; Martin Kircher; Arineh Khechaduri; Jennifer N Dines; Ronald J Hause; Smita Bhatia; William E Evans; Mary V Relling; Wenjian Yang; Jay Shendure; Douglas M Fowler
Journal:  Nat Genet       Date:  2018-05-21       Impact factor: 38.330

10.  Massively parallel characterization of CYP2C9 variant enzyme activity and abundance.

Authors:  Clara J Amorosi; Melissa A Chiasson; Matthew G McDonald; Lai Hong Wong; Katherine A Sitko; Gabriel Boyle; John P Kowalski; Allan E Rettie; Douglas M Fowler; Maitreya J Dunham
Journal:  Am J Hum Genet       Date:  2021-07-26       Impact factor: 11.025
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.